TransMedics Group, Inc. (TMDX) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 9 Buy, 3 Hold.
The consensus price target is $146.80 (low: $135.00, high: $166.00), representing an upside of 26.9% from the current price $115.68.
Analysts estimate Earnings Per Share (EPS) of $0.98 and revenue of $0.43B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $1.07 vs est $0.98 (beat +9.2%). 2025: actual $5.60 vs est $2.60 (beat +115.5%). Analyst accuracy: 69%.
TMDX Stock — 12-Month Price Forecast
$146.80
▲ +26.90% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for TransMedics Group, Inc., the average price target is $146.80, with a high forecast of $166.00, and a low forecast of $135.00.
The average price target represents a +26.90% change from the last price of $115.68.
Highest Price Target
$166.00
Average Price Target
$146.80
Lowest Price Target
$135.00
TMDX Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to TransMedics Group, Inc. in the past 3 months
EPS Estimates — TMDX
69%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $1.07
vs Est $0.98
▲ 8.4% off
2025
Actual $5.60
vs Est $2.60
▲ 53.6% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving.
Revenue Estimates — TMDX
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.442B
vs Est $0.430B
▲ 2.7% off
2025
Actual $0.605B
vs Est $0.601B
▲ 0.8% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
